Get the Stockscreener App
0.386
16.72%
0.0553
After Hours:
.39
0.004
+1.04%
Elevation Oncology Inc stock is traded at $0.386, with a volume of 2.68M.
It is up +16.72% in the last 24 hours and down -26.60% over the past month.
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
See More
Previous Close:
$0.3307
Open:
$0.3401
24h Volume:
2.68M
Relative Volume:
1.59
Market Cap:
$17.40M
Revenue:
-
Net Income/Loss:
$-41.95M
P/E Ratio:
-0.4651
EPS:
-0.83
Net Cash Flow:
$-38.34M
1W Performance:
+42.96%
1M Performance:
-26.60%
6M Performance:
-29.98%
1Y Performance:
-90.68%
1-Day Range:
$0.3268
$0.387
1-Week Range:
$0.255
$0.387
52-Week Range:
$0.221
$4.49
Elevation Oncology Inc Stock (ELEV) Company Profile
Name
Elevation Oncology Inc
Sector
Industry
Phone
(716) 371-1125
Address
101 FEDERAL STREET, BOSTON
Compare ELEV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELEV
Elevation Oncology Inc
|
0.386 | 17.40M | 0 | -41.95M | -38.34M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-25 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-21-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-25 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| May-30-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Dec-23-21 | Initiated | H.C. Wainwright | Buy |
View All
Elevation Oncology Inc Stock (ELEV) Latest News
GSK prepares to relaunch Blenrep; Activists challenge another ‘zombie’ biotech - BioPharma Dive
Elevation mulls strategic alternatives, including closure, amid activist pressure - PharmaLive
Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down - insights.citeline.com
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
Analysts Set Elevation Oncology, Inc. (NASDAQ:ELEV) PT at $3.39 - Defense World
Fierce Biotech Layoff Tracker 2025: Mural lays off 90%; Pfizer sells site, cuts staff - Fierce Biotech
Rare NRG1 Fusion Market to Reach New Heights in Growth by 2034, - openPR.com
Elevation Oncology opts for early term loan repayment By Investing.com - Investing.com South Africa
Elevation Oncology opts for early term loan repayment - Investing.com
Elevation Oncology IncTo Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022SEC Filing - MarketScreener
Elevation Oncology stock hits 52-week low at $0.24 By Investing.com - Investing.com Canada
Virtu Financial LLC Takes $36,000 Position in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Elevation Oncology’s Chief Medical Officer Steps Down - TipRanks
What is Elevation Oncology Inc (ELEV) Stock Return on Shareholders’ Capital? - Sete News
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 - Longview News-Journal
Elevation Oncology (NASDAQ:ELEV) Given “Equal Weight” Rating at Stephens - Defense World
Analysts Set Expectations for ELEV FY2029 Earnings - Defense World
Elevation Oncology (NASDAQ:ELEV) Cut to “Neutral” at Piper Sandler - The AM Reporter
Massachusetts-Based Elevation Oncology Cuts 70% of Workforce After Drug Setback - NewsBreak: Local News & Alerts
Elevation Oncology (NASDAQ:ELEV) Rating Lowered to “Market Perform” at Citizens Jmp - Defense World
Elevation Oncology (NASDAQ:ELEV) Rating Lowered to Neutral at Piper Sandler - Defense World
Elevation Oncology (NASDAQ:ELEV) Rating Lowered to Market Perform at Leerink Partners - Defense World
HC Wainwright Lowers Elevation Oncology (NASDAQ:ELEV) Price Target to $1.00 - Defense World
Elevation Oncology (NASDAQ:ELEV) Cut to “Hold” at Leerink Partnrs - Defense World
Elevation Oncology (NASDAQ:ELEV) Cut to Hold at Wedbush - Defense World
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives $6.83 Average Target Price from Analysts - Defense World
Elevation Oncology Plunges 42% on Ending Development of Lead Drug - MSN
Elevation Oncology stock rating cut amid ADC asset halt By Investing.com - Investing.com Canada
Elevation Oncology Plunges 42% On Ending Development Of Lead Drug - Barchart
Boston cancer biotech cuts 70% of staff - The Business Journals
Elevation Oncology downgraded as it halts lead asset on disappointing trials - Yahoo Finance
Tesla To $410? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Piper Sandler Downgrades Elevation Oncology to Neutral From Overweight, Adjusts Price Target to $0.70 From $10 - Marketscreener.com
Piper Sandler cuts Elevation Oncology stock rating to Neutral By Investing.com - Investing.com Canada
ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase - Benzinga
Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70% - Benzinga
Elevation Oncology stops work on ADC, lays off workers; AstraZeneca’s CEPI funding - Endpoints News
Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results - Benzinga
Elevation Oncology, Inc. Implements A Workforce Reduction of Approximately 70% -March 20, 2025 at 08:08 am EDT - Marketscreener.com
Elevation Oncology halts development of cancer drug EO-3021 By Investing.com - Investing.com Australia
Sector Update: Health Care Stocks Decline Pre-Bell Thursday - TradingView
Elevation Oncology tumbles after halting development of cancer drug - TradingView
Elevation Oncology Drops Potential Metastatic Cancer Drug, Evaluates Strategic Options; Shares Fall Pre-Bell - Marketscreener.com
Why Is Elevation Oncology Stock Falling In Pre-market? - Nasdaq
Elevation Oncology stock tumbles on halted drug development By Investing.com - Investing.com Canada
Elevation Oncology Restructures Amid EO-3021 Discontinuation - TipRanks
Elevation Oncology stock tumbles on halted drug development - Investing.com India
Elevation Oncology halts development of cancer drug EO-3021 - Investing.com India
Elevation Oncology Inc Stock (ELEV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):